Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donna Hansel

Anatomic Pathology Houston, TX Medical Doctor

NPI 1184735524 CMS profile 710687

1515 Holcombe Blvd, Houston, TX 77030

Open in the dashboard

General payments

$91,413

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$243,000 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Donna Hansel of Houston, TX is reported in the CMS Open Payments database as having received $91,413 across 66 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $243,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Anatomic Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,541 8
2024 General $454 1
2023 General $4,840 2
2022 General $5,121 7
2021 General $12,705 4
2020 General $12,748 8
2019 General $43,005 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Hansel
  • Anatomic Pathology median
  • Middle half of Anatomic Pathology
  • National median

In program year 2025, general payments to Donna Hansel were reported at $12,541. Among 419 Anatomic Pathology profiles paid that year, the median was $110 and the middle half received between $28 and $974.

Show as a table
Year Donna Hansel Anatomic Pathology median Middle half National median
2019 $43,005 $112 $31–$404 $163
2020 $12,748 $185 $25–$4,265 $114
2021 $12,705 $121 $24–$2,629 $132
2022 $5,121 $121 $31–$1,816 $149
2023 $4,840 $96 $28–$1,008 $160
2024 $454 $103 $28–$1,069 $164
2025 $12,541 $110 $28–$974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $53,399 33 payments
  2. AstraZeneca UK Limited $17,204 13 payments
  3. Daiichi Sankyo Inc. $9,673 2 payments
  4. E.R. Squibb & Sons, L.L.C. $4,395 8 payments
  5. Merck Sharp & Dohme Corporation $2,622 2 payments
  6. Janssen Global Services, LLC $2,600 1 payment
  7. Janssen Biotech, Inc. $1,170 1 payment
  8. Caris MPI, Inc. $187 4 payments
  9. Seattle Genetics, Inc. $83 1 payment
  10. Ferring Pharmaceuticals Inc. $82 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $76,847 33 payments
  2. Travel and Lodging $13,514 11 payments
  3. Food and Beverage $1,052 22 payments
Products named General payments · program years 2019–2025
  1. IMFINZI Cardiovascular And Metabolism $21,379 14 payments
  2. TAGRISSO $11,784 10 payments
  3. IMFINZI Oncology $11,495 3 payments
  4. ENHERTU $9,673 2 payments
  5. IMFINZI Oncology $5,867 4 payments
  6. OPDIVO $4,395 8 payments
  7. KEYTRUDA $2,622 2 payments
  8. BALVERSA $1,170 1 payment
  9. MI CANCER SEEK $187 4 payments
  10. PADCEV $83 1 payment
  11. Other $82 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$15,625

Medicare's payments for the services billed

Medicare patients

172

Average age 74

Services billed

349

23 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 40%
Ischemic heart disease 35%
Chronic kidney disease 33%
Diabetes 26%
Atrial fibrillation 19%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anatomic Pathology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record